Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My NCBI Filters

Results by year

Table representation of search results timeline featuring number of search results per year.

Year Number of Results
2011 1
2012 2
2013 1
2014 1
2015 1
2016 2
2017 3
2018 2
2019 9
2020 10
2021 19
2022 15
2023 13
2024 6

Text availability

Article attribute

Article type

Publication date

Search Results

69 results

Results by year

Filters applied: . Clear all
Page 1
Identification of potential resistance mechanisms and therapeutic targets for the relapse of BCMA CAR-T therapy in relapsed/refractory multiple myeloma through single-cell sequencing.
Li W, Zhang B, Cao W, Zhang W, Li T, Liu L, Xu L, Gao F, Wang Y, Wang F, Xing H, Jiang Z, Shi J, Bian Z, Song Y. Li W, et al. Among authors: shi j. Exp Hematol Oncol. 2023 May 8;12(1):44. doi: 10.1186/s40164-023-00402-5. Exp Hematol Oncol. 2023. PMID: 37158921 Free PMC article.
CCL17 acts as an antitumor chemokine in micromilieu-driven immune skewing.
Li Y, Cao H, Jiang Z, Yan K, Shi J, Wang S, Wang F, Wang W, Li X, Sun N, Liu L, Chen L, Chen Y, Guo R, Song Y. Li Y, et al. Among authors: shi j. Int Immunopharmacol. 2023 May;118:110078. doi: 10.1016/j.intimp.2023.110078. Epub 2023 Mar 29. Int Immunopharmacol. 2023. PMID: 37001380
Feasibility and tolerability of sintilimab plus anlotinib as the second-line therapy for patients with advanced biliary tract cancers: An open-label, single-arm, phase II clinical trial.
Jin S, Zhao R, Zhou C, Zhong Q, Shi J, Su C, Li Q, Su X, Chi H, Lu X, Jiang G, Chen R, Han J, Jiang M, Qiao S, Liu J, Song M, Song L, Du Y, Chang Z, Wang M, Dong M, Zhong Y, Yu P, Zhang X, Zong H. Jin S, et al. Among authors: shi j. Int J Cancer. 2023 Apr 15;152(8):1648-1658. doi: 10.1002/ijc.34372. Epub 2022 Dec 1. Int J Cancer. 2023. PMID: 36444498 Free article. Clinical Trial.
69 results